Correspondence to: Robert H. Shoemaker, Ph.D., Screening Technologies Branch, Bldg. 431A, National Cancer Institute- Frederick Cancer Research and Development Center, Frederick, MD 21702-1201(e-mail: shoemaker{at}dtpax2.ncifcrf.gov).
A wide variety of genetic and epigenetic factors have been
implicated as determinants of anticancer drug resistance. Some of these
are listed in Table 1. The growing body of published
information regarding the function of oncogenes, tumor suppressor
genes, cell cycle checkpoints, intracellular signaling cascades, and
mechanisms of apoptotic cell death is shifting the focus of research
toward microenvironmental and epigenetic factors. In this issue of the
Journal, Taylor et al. (1) add significantly to the knowledge
of epigenetic factors by documenting the effect of some
microenvironmental factors as regulators of proteins involved in
control of apoptosis following exposure to etoposide.
|
Studies of methotrexate resistance (6) revealed the phenomenon of gene amplification. Homogeneous staining regions in chromosomes present in drug-resistant cell populations were explained by amplification of dihydrofolate reductase genes. The demonstration that the somatic cell could undergo a change in gene copy number was contrary to the once-prevailing dogma of one gene-one polypeptide and helped revolutionize thinking about control of gene expression. Perhaps equally dramatic was the discovery of the phenomenon of multidrug resistance (7) and of the operation of p-glycoprotein as a membrane efflux pump that could reduce intracellular drug accumulation and thereby confer resistance to a broad range of structurally and mechanistically diverse drugs (8). Cloning and characterization of the MDR-1 gene encoding p-glycoprotein (9) provided further impetus for investigation of tumor cell genetic factors in drug resistance, such as the multidrug resistance-associated MRP gene (10). Immunocytochemical studies of expression of multidrug resistance-associated proteins (11), together with in vitro drug sensitivity data, have supported the concurrent operation of multiple drug resistance mechanisms within one tumor cell population. Furthermore, immunocytochemical studies of clinical samples (12) have demonstrated associations between expression of some multidrug resistance-associated proteins and clinical drug resistance.
However, the tumor microenvironment may also play a key role as a determinant of drug response. This is well illustrated by studies that reveal a difference in tumor cell response to drugs that are assayed in monolayer versus spheroid culture (13). The spheroid model has been shown to represent tissues that form cell-cell junctions and to invoke signaling cascades, which may be important features of the in vivo, and, hence, the clinical, microenvironment. Indeed, relatively anoxic cells in the interior of spheroids have been shown to elaborate vascular endothelial growth factor (14). Anoxic conditions have long been known to reduce tumor cell sensitivity to radiation and radiomimetic drugs (15) and now have been shown to modulate apoptotic cell death in a setting in which angiogenesis is inhibited (16). Alterations of the interaction of tumor cells with the extracellular matrix can result in activation of signal transduction cascades, which can affect tumor cell response to drugs in an epigenetic manner (17).
In their article, Taylor et al. (1) demonstrate that microenvironmental factors can regulate molecules involved in control of apoptotic cell death following exposure to etoposide. The researchers suggest that the observed survival-promoting mechanisms can act "to prevent drug-induced cell death resulting in pleiotropic drug resistance." Certainly, many other anticancer drugs are known to produce DNA damage and induce apoptosis, and it seems likely that the existence of epigenetic resistance mechanisms will prove to be a phenomenon of importance in cancer chemotherapy. The present article complements their previous work, which showed that microenvironmental factors within the germinal center act with Bcl-2 expression in reducing apoptotic cell death among and increasing clonogenic growth of lymphoma cells (18). Thus, a mechanistic basis for the operation of pharmacologic sanctuary sites for tumor cells could include both the presence of microenvironmental factors that suppress apoptosisresulting in pleiotropic drug resistanceas well as factors that limit the development of effective drug concentrations in cells sequestered within particular three-dimensional tumor masses. In such a scenario, the sequestered cells may also bear genetic changes conferring drug resistance.
The emerging information regarding epigenetic and microenvironmental factors in drug resistance should be considered in the broader context of tumor biology with the well-known caveats of tumor cell heterogeneity and genetic instability. In addition, the patient's genotype can potentially play an important role in resistance or sensitivity to a given treatment. For example, constitutional abnormalities in tumor suppressor gene function, such as those that occur in familial retinoblastoma, may modulate aspects of tumor cell response to chemotherapeutic drugs. Future advances in chemotherapy can build on this growing body of information to identify molecular targets that can be exploited for new drug discovery initiatives and to design more effective therapeutic regimens for existing drugs.
REFERENCES
1
Taylor ST, Hickman JA, Dive C. Epigenetic determinants of
resistance to etoposide regulation of Bcl-xL and Bax by tumor microenvironmental factors. J Natl Cancer Inst 2000;92:18-23.
2 Burchenal JH, Robinson E, Johnston SF, Kushida MN. The induction of resistance to 4-amino-N10-methyl-pteroylglutamic acid in a strain of transmitted mouse leukemia. Science 1950;111:116-7.
3 Burchenal JH, Cremer MA, Williams BS, Armstrong RA. Sterilization of leukemia cells in vivo and in vitro. Cancer Res1951 ;11:700-5.[Medline]
4 Law LW. Origin of the resistance of leukaemic cells to folic acid antagonists. Nature 1952;169:628-9.[Medline]
5 Law LW. Resistance in leukemic cells to an adenine antagonist, 6-mercaptopurine. Proc Soc Exp Biol Med 1953;84:409-12.
6 Nunberg JH, Kaufman RJ, Schimke RT, Urlaub G, Chasin LA. Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexateresistant Chinese hamster ovary cell line. Proc Natl Acad Sci U S A 1978;75:5553-6.[Abstract]
7 Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174-84.[Medline]
8 Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-8.[Medline]
9 Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.Proc Natl Acad Sci USA 1986;83: 4538-42.[Abstract]
10 Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.[Medline]
11 Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996;65:230-7.[Medline]
12 Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230-7.[Abstract]
13 Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 1993;90:3294-8.[Abstract]
14 Waleh NS, Brody MD, Knapp MA, Mendonca HL, Lord EM, Koch CJ, et al. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res 1995;55:6222-6.[Abstract]
15 Tannock I. Oxygen distribution in tumours: influence on cell proliferation and implications for tumour therapy. Adv Exp Med Biol1976 ;75:597-603.[Medline]
16
Gee MS, Koch CJ, Evans SM, Jenkins WT, Pletcher CH Jr,
Moore JS, et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control
by recombinant interleukin 12. Cancer Res 1999;59: 4882-9.
17 Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des 1999;14:153-68.[Medline]
18 Walker A, Taylor ST, Hickman JA, Dive C. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Res 1997;57:1939-45.[Abstract]
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |